![]() ![]() After 12 months, the serum phosphorus levels were higher in the treatment group than in the control group (5.4 ± 1.1 vs 4.6 ± 0.9 mg/dL, P =.001). ![]() At baseline, the serum phosphorus levels were lower and the calcium × phosphorus product levels were higher in the control group than in the treatment group. ![]() The incidence of fractures was higher in the control group than in the treatment group (6/60, 10% vs 8/120, 6.7%). The occurrence of fractures was compared between the control and the treatment groups. The osteoid mineralization index, the osteoprotegerin/receptor activator of nuclear factor κB ligand ratio, and the estimated glomerular filtration rate were compared between the control and the treatment groups. The serum phosphorus, calcium, parathyroid hormone, intact-parathyroid hormone, and calcium × phosphorus product levels were compared between the 2 groups. The occurrence of fracture was assessed in both groups. Intradialytic phosphorus supplementation was provided during the hemodialysis session. Of these patients, 120 were randomized into the control group and 182 were randomized into the treatment group. A total of 302 patients with end-stage renal disease receiving hemodialysis were enrolled into this study. ![]() We aimed to determine whether intradialytic phosphorus supplementation can reduce fracture risk and to evaluate the parameters associated with the efficacy of phosphate supplements. 1].The Role of Intradialytic Phosphate Supplementation on Fracture Risk in Chronic Hemodialysis Patients. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |